Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) poses a significant risk of metastasis and relapse, demanding effective neoadjuvant chemotherapy strategies. This retrospective study aimed to compare the outcomes of a sole docetaxel versus a docetaxel and capecitabine combination (TX) regimen as a neoadjuvant treatment for triple-negative breast cancer. The current retrospective analysis was conducted at the oncology department of Nishtar Hospital Multan and encompassed 80 randomly assigned female patients with triple-negative breast cancer between September 17, 2021, and December 31, 2022. They were further divided into two groups. The TX regimen (docetaxel 75 mg/m2 d1 with capecitabine 800 mg/m2 twice d1-14, q3w) was given to forty patients in the first group named the TX group, where the T regimen (docetaxel 75 mg/m2 d1 q3w) was given to other forty patients assigned in the second group called as T group, over four cycles. The primary endpoint was achieving a pathological complete response (pCR) in the breast, with secondary objectives including pCR in both the breast and axilla, invasive disease-free survival (iDFS), overall 0ne year survival (OS), and safety assessments. In the retrospective analysis, 21 patients in the TX group and 5 in the T group achieved pCR (52.5% vs. 12.5%, p=0.014), demonstrating a statistically significant superiority of the TX regimen. The TX regimen substantially increased pCR incidence (95% CI 2.3-47.1%; p = 0.028) within a subgroup characterized by a high Ki-67 level. The TX group showed a higher incidence of hand-foot syndrome and a statistically insignificant (p > 0.05) incidence of alopecia, presenting a manageable toxicity profile. Comparable iDFS and OS rates were observed in both groups throughout the 12-month average follow-up period. This retrospective analysis indicates that the TX regimen yielded significantly superior results, with a marked increase in pCR rates, particularly in the high Ki-67 subgroup. The observed toxicity profile was manageable, emphasizing the clinical benefits of incorporating capecitabine with docetaxel in neoadjuvant chemotherapy for triple-negative breast cancer patients.
No takes yet. Share an insight, caveat, or question.
KHAN et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: